Ekf Diagnostics Share Price (EKF)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Ekf Diagnostics Holdings Plc	LSE:EKF	London	Ordinary Share	GB0031509804	ORD 1P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	-0.65p	-1.93%	33.10p	76,142	16:35:22

Bid Price		Offer Price	High Price	Low Price	Open Price
32.50p		33.70p	33.70p	33.40p	33.50p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Health Care Equipment & Services	42.54	12.17	2.21	15.0	151.5

Related Shares
Smith & Nephew (SN.), Nmc Health (NMC), Widecells (WDC), Physiomics (PYC)

Ekf Diagnostics (EKF) Latest News

Ekf Diagnostics News

Date	Time	Source	Headline
02/5/2019	11:21	UKREG	EKF Diagnostics Holdings PLC Result of AGM
26/4/2019	18:20	UKREG	EKF Diagnostics Holdings PLC Acquisition of further interest in Renalytix..
25/4/2019	07:00	UKREG	EKF Diagnostics Holdings PLC Posting of AR & Accounts and Notice of AGM
13/3/2019	12:35	ALNC	EKF Diagnostics 2018 Profit Jumps On Lower Costs, Higher Revenue
13/3/2019	07:01	UKREG	EKF Diagnostics Holdings PLC Final Results
08/3/2019	07:01	UKREG	EKF Diagnostics Holdings PLC Notice of Results
20/2/2019	10:10	ALNC	EKF Diagnostics Gains US FDA Clearance For Quo-Test Analyser
20/2/2019	07:00	UKREG	EKF Diagnostics Holdings PLC US FDA approval for Quo-Test analyser
22/1/2019	07:00	UKREG	EKF Diagnostics Holdings PLC Update on McKesson US distribution agreement
21/1/2019	07:00	UKREG	Renalytix AI PLC Clarification re. lock-up restrictions

More Ekf Diagnostics News

Ekf Diagnostics Takeover Rumours

Ekf Diagnostics (EKF) Share Charts

1 Year Ekf Diagnostics Chart

1 Month Ekf Diagnostics Chart

Intraday Ekf Diagnostics Chart

Ekf Diagnostics (EKF) Discussions and Chat

Ekf Diagnostics Forums and Chat

Date	Time	Title	Posts
17/5/2019	07:30	EKF Diagnostics - Growth by acquisition, expertise and special relationships	1,356
27/7/2011	06:35	EKF Diagnostics – Growth by acquisition, expert knowledge and special relationsh	7
25/7/2011	14:22	EKF Diagnostics	209
13/7/2010	21:15	EFK DIAGNOSTICS	6

Add a New Thread

Ekf Diagnostics (EKF) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all Ekf Diagnostics trades in real-time

Ekf Diagnostics (EKF) Top Chat Posts

Date	Subject
19/5/2019 09:20	Ekf Diagnostics Daily Update: Ekf Diagnostics Holdings Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 33.75p. Ekf Diagnostics Holdings Plc has a 4 week average price of 33p and a 12 week average price of 29p. The 1 year high share price is 41.10p while the 1 year low share price is currently 23.85p. There are currently 457,632,749 shares in issue and the average daily traded volume is 79,868 shares. The market capitalisation of Ekf Diagnostics Holdings Plc is £151,476,439.92. Read Full Thread Reply
09/2/2019 09:04	macarona: Hi Wan, what do you see as the fair share price value for EKF? Read Full Thread Follow Reply
28/10/2018 06:56	wan: Cambridgedon...If we take 40p (Market cap £183m) as having fully realised, in share price terms, the soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) biomarker assets, and then factor in EKF receiving in round figures £25m (20,964,524 RENX Shares @ £1.21) for those assets, that should result in a ex distribution share price (reduction) to circa 35p (market cap £160m) However, 40p may have been driven by increased demand ahead of the spin-out, but even if we targeted 35p as discounting the effects of such demand, then we would arrive at an ex distribution share price of 30p (hence previous comments) From the point of announcing the spin-out (11th Jan 2018 share price circa 26p), if one looks at specific announcements and other stated growth initiatives, which are over and above that associated with Renaltix, then there is very good reason to expect an increase in organic growth over the near term and a significant increase in growth over the medium term. Read Full Thread Follow Reply
23/10/2018 15:34	wan: Macarona...As discussed on here previously, the current EKF share price appears to have already reflected the distribution, presumably because the announcements had effectively flagged when and by how much, but as I said this morning, time will tell None of us can predict what will happen when Renalytix commences trading, but having done quite a bit of research I am quite hopeful about the near to medium term prospects for Renalytix (including potential news flow), and maybe there will be good demand for the shares (other AI in healthcare companies are certainly attaining very high valuations). So my decision to buy more EKF shares was based on the current share price pullback and the near term prospects and potential news flow for EKF, and also about getting the maximum exposure to Renalytix ahead of any high demand and potentially being scaled back on the Restricted Offer, via which I intend to also add (and possibly when trading commences too). Best wishes to all EKF and Renalytix shareholders. Read Full Thread Follow Reply
23/10/2018 08:13	cambridgedon: Hi All, Thanks Wan. The ratio of new shares to old is a little better than we originally calculated. Surprised at the record date but not complaining as added recently. I'll be happier when the EKF price gets back to the high 30's where it should be all things considered. CD Read Full Thread Follow Reply
20/10/2018 08:32	wan: Cambridgedon...As I said previously, there is a lot to digest! I assume we will know early next week regarding the de minimis threshold, but one assumes that what ever that threshold is, it will then be based on a round number. There are 457,554,636 shares in issue, which in your scenario would be closer to 45 or 46 shares per 1000 EKF shares. As Ingroid suggests, the current EKF share price does appear to reflect the distribution (as per the case when a stock goes ex dividend), but you will have to wait six months to ultimately realise it (if you wanted to sell). Personally speaking, I was not looking to immediately sell the Renalytix shares anyway (as I had good reasons to think that the investment prospect would be a good one), so I am not fazed by the lock-up period. I note Renalytix will also pay back all the EKF loans, so there is some cash to come back too. Overall, I am very impressed with the know-how and expertise behind Renalytix, including how they have assessed the proposition and positioned Renalytix to address the market, which is indeed very large (as are the resulting savings and resultant business proposition). EKF clearly see a good investment proposition too, as they intend to take part in the fund raise and have a notifiable interest in Renalytix. Renalytix aside, I still think that EKF is an excellent long term investment. Read Full Thread Follow Reply
16/10/2018 12:59	ingroid: Share price now ex distribution.Have copy of documents for the restricted shares and as far as i see you attach a cheque and apply for equivalent number of shares. It will be left to you . Obviously if oversubscribed you will be scaled back accordingly. Read Full Thread Follow Reply
16/10/2018 10:50	cambridgedon: Don't bother to call the "helpline", they have not even heard of EKF nor Renalytix AI! I've told N+1 Singer who were not impressed. From what I can gather the ratio of free shares to your existing holding will not be known until after the GM on Friday or some other later date. As to how many new shares you can subscribe for at £1.21, should you wish, I've no idea. If Wan or anyone else can shed some light on all of this I'd be grateful. Also, the share price keeps heading lower too. All very odd. CD Read Full Thread Follow Reply
27/9/2018 07:56	wan: I note yesterday that Peel Hunt has initiated coverage of Sensyne Health Plc Ord 10p [LON:SENS] with a buy investment rating and price target of 261p. Current share price is 198p. I have highlighted Sensyne previously, Sensyne combines experience in AI, digital health and life sciences. Read Full Thread Follow Reply
09/4/2018 09:28	wan: N+1 Singer analyst Chris Glasper has published commentary today in which he described news from EKF of FDA 510k approval and CLIA Waiver as “very positive news” and asserts that “the potential opportunity is material for EKF”, with a “$35m+ market for point of care testing in the US to go at”. Forecasts remain unchanged at the moment but he writes: “We make no changes to our estimates, pending confirmation of the commercial strategy, which we expect in the coming months. We continue to see meaningful upside to the current share price on this and other opportunities in the pipeline.” N+1 Singer currently forecast £43.4m revenue for 2018, adj EBITDA of £10m and £7.5m adj PBT. For 2019 these rise to £44.7m, adj EBITDA of £10.8m and adj PBT of £8.0m. (END) Indeed I concur ;-) I also see material upside. Read Full Thread Follow Reply
20/7/2016 11:58	andrewbaker: The recent share purchase (see news articles on quotes page) suggests that the company is prospering/will prosper greatly going forward. The weakness of the £ sterling combined with sales in US$ and other currencies is a big boost for many British businesses; and if their core product(s) are improving in sales/prospects too, that's a double bonus. A continuing rise in the EKF share price looks very much on the cards right now and going forward. Read Full Thread Follow Reply

Ekf Diagnostics share price data is direct from the London Stock Exchange

Your Recent History

LSE

EKF

Ekf Diagno..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20190519 20:19:18